35 results about "Posterior capsule opacification" patented technology

The present invention relates to amphiphilic block copolymers comprising at least one block of hydrophilic units and at least one block of hydrophobic units, wherein at least one hydrophobic block contains siloxane units. The present invention may be particularly useful as a tissue adhesive or as a coating for an intraocular lens (IOL). As an IOL coating, copolymers according to the invention may be used, for example, to promote tissue adhesion for the prevention of posterior capsule opacification.

The present invention relates to intraocular lenses. At present, the polymethyl methacrylate (PMMA) intraocular lens commonly used in clinic for the treatment of cataract often causes inflammation after being implanted in the human body. Posterior capsule turbidity is also the main complication after cataract surgery. To solve these problems, the present invention selects antineoplastic drugs According to the weak penetrability of chitosan nanoparticles in the eye and the characteristics that the phagocytosis of conjunctival epithelial cells on nanoparticles is related to the size of the nanoparticles, chitosan-polyacrylic acid was used as a carrier to prepare fluorouracil nanoparticles Formulation, mixed coating on the surface of PMMA intraocular lens. The present invention also provides the preparation method of the above-mentioned intraocular lens. The invention not only increases the biocompatibility of the intraocular lens, inhibits the opacity of the posterior capsule after the implantation of the intraocular lens, but also prevents the anterior membrane and post-cataract after the implantation of the intraocular lens.

An intraocular lens for inhibiting posterior and anterior capsular opacification, or secondary cataract, includes an optic having a periphery provided with sharp bevels extending along arc segments defined by the juncture of the haptic-optic points of attachment and adjacent both the anterior and posterior optic surfaces.

An intraocular lens (IOL) for implantation within a capsular bag includes an optic and a plurality of haptics. The optics has an anterior optic face and a posterior optic face joined by a peripheral wall. The peripheral wall includes a straight portion of uniform width extending posteriorly from the anterior optic face to a flare point and a flared optic edge. The flared optic edge extends posteriorly and widens from the flare point and meets the posterior optic face at a sharp optic corner. Each of the haptics is coupled to the optic at the peripheral wall at respective haptic-optic junctions. The flared optic edge surrounds the peripheral wall between the haptic-optic junctions.

The invention relates to an artificial lens with a hydrophilic-medicine sustained release synergistic function, and a preparation method thereof. A medicine-loading-hydrophilic multifunctional coatingis modified on the surface of the artificial lens, and the synergistic effect of resisting cell adhesion at an early stage after implantation and resisting lens epithelia cell proliferation at middleand late stage is achieved, so that the occurrence rate of posterior capsule opacification can be reduced and a high-biocompatibility artificial lens is obtained; a hydrophilic-medicine-loading multifunctional modification layer is constructed on the surface of the artificial lens by a one-pot method, the manufacturing process is simple and low in cost, the tedious steps required by surface modification in the past are avoided, and the artificial lens can be applied to the surface of a three-dimensional implantable device with various complex shape structures. The manufactured zwitterionic modified artificial lens is convenient to disinfect, packaging and transport, and is an artificial lens industrialized product which is low in cost, convenient and practical.

The invention discloses an application of pirfenidone in the preparation of medicaments for controlling proliferative diseases after an ophthalmologic operation and eye drops thereof. According to the invention, pirfenidone is prepared into the eye drops. Experiments show that pirfenidone has good stability and good ocular tissue permeability, can inhibit HLECs migration and propagation, and has no cytotoxicity to HLECs within the action range (0-1mg / ml). With pirfenidone being within the range of 0-1%, the eye drops are continuously applied on eyes within a month with safety and with no obvious toxic and side effect. Pirfenidone can be used to delay the generation of PCO after the rabbit corneal Phaco operation, reduce HLECs propagation and minimize the shield of PCO to an optical region. In addition, there is no obvious ocular surface injury or postoperative inflammation aggravation and severe adverse reaction after PFD is applied in the rabbit corneal Phaco operation. Therefore, pirfenidone can be used to control proliferative diseases after an ophthalmologic operation, especially posterior capsule opacification generated after a cataract surgery.